Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EBITDA (2019 - 2026)

InMed Pharmaceuticals has reported EBITDA over the past 5 years, most recently at -$2.1 million for Q4 2025.

  • For Q4 2025, EBITDA rose 6.21% year-over-year to -$2.1 million; the TTM value through Dec 2025 reached -$7.9 million, changed 0.44%, while the annual FY2025 figure was -$7.9 million, 3.1% up from the prior year.
  • EBITDA for Q4 2025 was -$2.1 million at InMed Pharmaceuticals, down from -$1.8 million in the prior quarter.
  • Over five years, EBITDA peaked at -$472234.0 in Q2 2023 and troughed at -$7.9 million in Q2 2022.
  • A 5-year average of -$2.6 million and a median of -$2.1 million in 2022 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: skyrocketed 94.0% in 2023 and later tumbled 329.61% in 2024.
  • Year by year, EBITDA stood at -$4.3 million in 2021, then skyrocketed by 50.94% to -$2.1 million in 2022, then increased by 22.39% to -$1.6 million in 2023, then crashed by 37.47% to -$2.2 million in 2024, then increased by 6.21% to -$2.1 million in 2025.
  • Business Quant data shows EBITDA for INM at -$2.1 million in Q4 2025, -$1.8 million in Q3 2025, and -$1.8 million in Q2 2025.